Cargando…

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer

BACKGROUND: The course of health-related quality of life (HRQOL) during and after completion of neoadjuvant chemoradiotherapy (nCRT) for esophageal or junctional carcinoma is unknown. METHODS: This study was a multicenter prospective cohort investigation. Patients with esophageal or cancer to be tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Noordman, B. J., Verdam, M. G. E., Onstenk, B., Heisterkamp, J., Jansen, W. J. B. M., Martijnse, I. S., Lagarde, S. M., Wijnhoven, B. P. L., Acosta, C. M. M., van der Gaast, A., Sprangers, M. A. G., van Lanschot, J. J. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864114/
https://www.ncbi.nlm.nih.gov/pubmed/31620943
http://dx.doi.org/10.1245/s10434-019-07779-w
_version_ 1783471827502235648
author Noordman, B. J.
Verdam, M. G. E.
Onstenk, B.
Heisterkamp, J.
Jansen, W. J. B. M.
Martijnse, I. S.
Lagarde, S. M.
Wijnhoven, B. P. L.
Acosta, C. M. M.
van der Gaast, A.
Sprangers, M. A. G.
van Lanschot, J. J. B.
author_facet Noordman, B. J.
Verdam, M. G. E.
Onstenk, B.
Heisterkamp, J.
Jansen, W. J. B. M.
Martijnse, I. S.
Lagarde, S. M.
Wijnhoven, B. P. L.
Acosta, C. M. M.
van der Gaast, A.
Sprangers, M. A. G.
van Lanschot, J. J. B.
author_sort Noordman, B. J.
collection PubMed
description BACKGROUND: The course of health-related quality of life (HRQOL) during and after completion of neoadjuvant chemoradiotherapy (nCRT) for esophageal or junctional carcinoma is unknown. METHODS: This study was a multicenter prospective cohort investigation. Patients with esophageal or cancer to be treated with nCRT plus esophagectomy were eligible for inclusion in the study. The HRQOL of the patients was measured with European Organization for Research and Treatment of Cancer QLQ-C30, QLQ-OG25, and QLQ-CIPN20 questionnaires before and during nCRT, then 2, 4, 6, 8, 10, 12, 14, and 16 weeks after nCRT and before surgery. Predefined end points were based on the hypothesized impact of nCRT. The primary end points were physical functioning, odynophagia, and sensory symptoms. The secondary end points were global quality of life, fatigue, weight loss, and motor symptoms. Mixed modeling analysis was used to evaluate changes over time. RESULTS: Of 106 eligible patients, 96 (91%) were included in the study. The rate of questionnaires returned ranged from 94% to 99% until week 12, then dropped to 78% in week 16 after nCRT. A negative impact of nCRT on all HRQOL end points was observed during the last cycle of nCRT (all p < 0.001) and 2 weeks after nCRT (all p < 0.001). Physical functioning, odynophagia, and sensory symptoms were restored to pretreatment levels respectively 8, 4, and 6 weeks after nCRT. The secondary end points were restored to baseline levels 4–6 weeks after nCRT. Odynophagia, fatigue, and weight loss improved after nCRT compared with baseline levels at respectively 6 (p < 0.001), 16 (p = 0.001), and 12 weeks (p < 0.001). CONCLUSION: After completion of nCRT for esophageal cancer, HRQOL decreases significantly, but all HRQOL end points are restored to baseline levels within 8 weeks. Odynophagia, fatigue, and weight loss improved 6–16 weeks after nCRT compared with baseline levels. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-019-07779-w) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6864114
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-68641142019-12-05 Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer Noordman, B. J. Verdam, M. G. E. Onstenk, B. Heisterkamp, J. Jansen, W. J. B. M. Martijnse, I. S. Lagarde, S. M. Wijnhoven, B. P. L. Acosta, C. M. M. van der Gaast, A. Sprangers, M. A. G. van Lanschot, J. J. B. Ann Surg Oncol Thoracic Oncology BACKGROUND: The course of health-related quality of life (HRQOL) during and after completion of neoadjuvant chemoradiotherapy (nCRT) for esophageal or junctional carcinoma is unknown. METHODS: This study was a multicenter prospective cohort investigation. Patients with esophageal or cancer to be treated with nCRT plus esophagectomy were eligible for inclusion in the study. The HRQOL of the patients was measured with European Organization for Research and Treatment of Cancer QLQ-C30, QLQ-OG25, and QLQ-CIPN20 questionnaires before and during nCRT, then 2, 4, 6, 8, 10, 12, 14, and 16 weeks after nCRT and before surgery. Predefined end points were based on the hypothesized impact of nCRT. The primary end points were physical functioning, odynophagia, and sensory symptoms. The secondary end points were global quality of life, fatigue, weight loss, and motor symptoms. Mixed modeling analysis was used to evaluate changes over time. RESULTS: Of 106 eligible patients, 96 (91%) were included in the study. The rate of questionnaires returned ranged from 94% to 99% until week 12, then dropped to 78% in week 16 after nCRT. A negative impact of nCRT on all HRQOL end points was observed during the last cycle of nCRT (all p < 0.001) and 2 weeks after nCRT (all p < 0.001). Physical functioning, odynophagia, and sensory symptoms were restored to pretreatment levels respectively 8, 4, and 6 weeks after nCRT. The secondary end points were restored to baseline levels 4–6 weeks after nCRT. Odynophagia, fatigue, and weight loss improved after nCRT compared with baseline levels at respectively 6 (p < 0.001), 16 (p = 0.001), and 12 weeks (p < 0.001). CONCLUSION: After completion of nCRT for esophageal cancer, HRQOL decreases significantly, but all HRQOL end points are restored to baseline levels within 8 weeks. Odynophagia, fatigue, and weight loss improved 6–16 weeks after nCRT compared with baseline levels. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1245/s10434-019-07779-w) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-10-16 2019 /pmc/articles/PMC6864114/ /pubmed/31620943 http://dx.doi.org/10.1245/s10434-019-07779-w Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Thoracic Oncology
Noordman, B. J.
Verdam, M. G. E.
Onstenk, B.
Heisterkamp, J.
Jansen, W. J. B. M.
Martijnse, I. S.
Lagarde, S. M.
Wijnhoven, B. P. L.
Acosta, C. M. M.
van der Gaast, A.
Sprangers, M. A. G.
van Lanschot, J. J. B.
Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title_full Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title_fullStr Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title_full_unstemmed Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title_short Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer
title_sort quality of life during and after completion of neoadjuvant chemoradiotherapy for esophageal and junctional cancer
topic Thoracic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864114/
https://www.ncbi.nlm.nih.gov/pubmed/31620943
http://dx.doi.org/10.1245/s10434-019-07779-w
work_keys_str_mv AT noordmanbj qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT verdammge qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT onstenkb qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT heisterkampj qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT jansenwjbm qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT martijnseis qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT lagardesm qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT wijnhovenbpl qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT acostacmm qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT vandergaasta qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT sprangersmag qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer
AT vanlanschotjjb qualityoflifeduringandaftercompletionofneoadjuvantchemoradiotherapyforesophagealandjunctionalcancer